Rajeev Vibhakar
Concepts (400)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 37 | 2024 | 191 | 9.460 |
Why?
| Cerebellar Neoplasms | 27 | 2024 | 150 | 7.290 |
Why?
| Rhabdoid Tumor | 10 | 2025 | 95 | 3.610 |
Why?
| Glioma | 16 | 2025 | 348 | 3.400 |
Why?
| Brain Neoplasms | 23 | 2025 | 1145 | 3.160 |
Why?
| Gene Expression Regulation, Neoplastic | 26 | 2025 | 1336 | 2.820 |
Why?
| Radiation Tolerance | 7 | 2022 | 98 | 2.470 |
Why?
| Cell Cycle Proteins | 8 | 2022 | 584 | 2.260 |
Why?
| Cell Proliferation | 25 | 2025 | 2373 | 1.710 |
Why?
| Cell Line, Tumor | 33 | 2025 | 3186 | 1.700 |
Why?
| SMARCB1 Protein | 3 | 2025 | 29 | 1.600 |
Why?
| Teratoma | 5 | 2022 | 103 | 1.560 |
Why?
| Protein-Tyrosine Kinases | 4 | 2020 | 431 | 1.380 |
Why?
| Proto-Oncogene Proteins c-myc | 5 | 2024 | 131 | 1.370 |
Why?
| Ependymoma | 10 | 2024 | 161 | 1.310 |
Why?
| Pyrazoles | 7 | 2022 | 404 | 1.170 |
Why?
| Nuclear Proteins | 9 | 2023 | 660 | 1.170 |
Why?
| Apoptosis | 19 | 2024 | 2492 | 1.110 |
Why?
| Proto-Oncogene Proteins | 4 | 2022 | 636 | 1.110 |
Why?
| Biomarkers, Tumor | 9 | 2021 | 1164 | 1.030 |
Why?
| Pyrimidines | 8 | 2019 | 459 | 0.950 |
Why?
| Sirtuin 2 | 1 | 2025 | 24 | 0.950 |
Why?
| Molecular Targeted Therapy | 4 | 2021 | 391 | 0.950 |
Why?
| Cyclin-Dependent Kinase 6 | 4 | 2020 | 40 | 0.950 |
Why?
| Brain Stem Neoplasms | 4 | 2021 | 81 | 0.950 |
Why?
| Antineoplastic Agents | 10 | 2022 | 2046 | 0.920 |
Why?
| Radiation-Sensitizing Agents | 2 | 2016 | 39 | 0.890 |
Why?
| Cell Transformation, Neoplastic | 2 | 2019 | 326 | 0.860 |
Why?
| Neoplastic Stem Cells | 4 | 2025 | 378 | 0.830 |
Why?
| Genes, myc | 3 | 2020 | 49 | 0.820 |
Why?
| MicroRNAs | 5 | 2020 | 679 | 0.810 |
Why?
| Pyrimidinones | 4 | 2020 | 102 | 0.800 |
Why?
| Hedgehog Proteins | 7 | 2022 | 188 | 0.800 |
Why?
| Cellular Senescence | 3 | 2019 | 181 | 0.800 |
Why?
| Cell Cycle | 11 | 2017 | 588 | 0.740 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 64 | 0.740 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.720 |
Why?
| Receptor, trkB | 1 | 2021 | 30 | 0.710 |
Why?
| Anilides | 3 | 2019 | 70 | 0.700 |
Why?
| DNA Repair | 2 | 2024 | 210 | 0.690 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 60 | 0.690 |
Why?
| Gene Expression Profiling | 15 | 2024 | 1687 | 0.680 |
Why?
| Central Nervous System Neoplasms | 4 | 2019 | 148 | 0.660 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 36 | 0.660 |
Why?
| Humans | 87 | 2025 | 129625 | 0.620 |
Why?
| Deoxycytidine | 1 | 2020 | 164 | 0.620 |
Why?
| Pteridines | 2 | 2016 | 20 | 0.610 |
Why?
| Cerebellum | 5 | 2022 | 218 | 0.610 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 477 | 0.600 |
Why?
| Oligonucleotide Array Sequence Analysis | 10 | 2016 | 756 | 0.590 |
Why?
| Transcription Factors | 6 | 2023 | 1647 | 0.580 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 507 | 0.570 |
Why?
| Histones | 4 | 2020 | 589 | 0.570 |
Why?
| Glioblastoma | 3 | 2023 | 322 | 0.560 |
Why?
| Xenograft Model Antitumor Assays | 7 | 2024 | 808 | 0.540 |
Why?
| RNA, Small Interfering | 4 | 2022 | 591 | 0.530 |
Why?
| Blotting, Western | 8 | 2019 | 1206 | 0.530 |
Why?
| Vinblastine | 1 | 2016 | 70 | 0.530 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.520 |
Why?
| Radiation, Ionizing | 3 | 2022 | 76 | 0.520 |
Why?
| Bilirubin | 1 | 2016 | 96 | 0.520 |
Why?
| Vincristine | 1 | 2016 | 108 | 0.510 |
Why?
| Cell Survival | 8 | 2019 | 1076 | 0.510 |
Why?
| Infratentorial Neoplasms | 3 | 2024 | 55 | 0.500 |
Why?
| Mice | 19 | 2025 | 16961 | 0.490 |
Why?
| Tumor Cells, Cultured | 7 | 2020 | 943 | 0.480 |
Why?
| Enzyme Inhibitors | 6 | 2020 | 827 | 0.480 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 132 | 0.480 |
Why?
| Mutation | 7 | 2022 | 3717 | 0.470 |
Why?
| Child | 31 | 2025 | 20884 | 0.470 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2012 | 63 | 0.470 |
Why?
| Transcriptome | 5 | 2022 | 876 | 0.450 |
Why?
| Cell Differentiation | 7 | 2025 | 1891 | 0.440 |
Why?
| RNA, Messenger | 7 | 2014 | 2708 | 0.440 |
Why?
| Histone Deacetylase Inhibitors | 3 | 2023 | 209 | 0.440 |
Why?
| Repressor Proteins | 3 | 2022 | 406 | 0.390 |
Why?
| Animals | 20 | 2025 | 35391 | 0.380 |
Why?
| Piperazines | 3 | 2022 | 340 | 0.360 |
Why?
| Child, Preschool | 18 | 2021 | 10490 | 0.360 |
Why?
| Prognosis | 9 | 2020 | 3774 | 0.350 |
Why?
| Azepines | 3 | 2019 | 88 | 0.350 |
Why?
| Epigenesis, Genetic | 4 | 2021 | 617 | 0.340 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 949 | 0.340 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2020 | 17 | 0.340 |
Why?
| Intracellular Space | 1 | 2010 | 69 | 0.330 |
Why?
| Chromatin | 4 | 2020 | 479 | 0.330 |
Why?
| Genes, Tumor Suppressor | 2 | 2007 | 87 | 0.330 |
Why?
| Neoplasm Proteins | 2 | 2012 | 419 | 0.330 |
Why?
| Reactive Oxygen Species | 2 | 2022 | 593 | 0.320 |
Why?
| Cisplatin | 3 | 2016 | 299 | 0.310 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1560 | 0.310 |
Why?
| Real-Time Polymerase Chain Reaction | 4 | 2014 | 329 | 0.310 |
Why?
| Drug Screening Assays, Antitumor | 4 | 2021 | 191 | 0.300 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2019 | 69 | 0.300 |
Why?
| Protein Kinase Inhibitors | 2 | 2014 | 887 | 0.300 |
Why?
| Quinazolines | 2 | 2022 | 243 | 0.290 |
Why?
| NF-kappa B | 4 | 2023 | 665 | 0.290 |
Why?
| B7 Antigens | 2 | 2020 | 12 | 0.270 |
Why?
| Mice, Nude | 3 | 2020 | 682 | 0.270 |
Why?
| DNA-Binding Proteins | 3 | 2017 | 1445 | 0.270 |
Why?
| Aurora Kinases | 3 | 2012 | 28 | 0.270 |
Why?
| Aurora Kinase A | 3 | 2012 | 54 | 0.260 |
Why?
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 487 | 0.260 |
Why?
| Combined Modality Therapy | 6 | 2019 | 1203 | 0.260 |
Why?
| Signal Transduction | 9 | 2021 | 4931 | 0.260 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2019 | 210 | 0.260 |
Why?
| Single-Cell Analysis | 4 | 2022 | 274 | 0.250 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2020 | 48 | 0.250 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 41 | 0.250 |
Why?
| Autophagy | 2 | 2019 | 266 | 0.250 |
Why?
| Neoplasm Recurrence, Local | 4 | 2022 | 958 | 0.250 |
Why?
| Epigenomics | 3 | 2020 | 110 | 0.240 |
Why?
| Triazoles | 2 | 2019 | 148 | 0.240 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 374 | 0.240 |
Why?
| Gene Fusion | 1 | 2025 | 25 | 0.240 |
Why?
| Bone Morphogenetic Proteins | 2 | 2019 | 129 | 0.240 |
Why?
| Protein-Arginine N-Methyltransferases | 1 | 2025 | 28 | 0.230 |
Why?
| Phenanthrenes | 1 | 2024 | 12 | 0.230 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2005 | 99 | 0.230 |
Why?
| Diterpenes | 1 | 2024 | 32 | 0.230 |
Why?
| Epoxy Compounds | 1 | 2024 | 33 | 0.220 |
Why?
| Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.220 |
Why?
| Abnormalities, Multiple | 1 | 2005 | 179 | 0.220 |
Why?
| Gene Rearrangement | 1 | 2025 | 148 | 0.220 |
Why?
| Female | 25 | 2025 | 68734 | 0.220 |
Why?
| Survival Rate | 5 | 2020 | 1872 | 0.220 |
Why?
| Drug Resistance, Neoplasm | 2 | 2019 | 752 | 0.210 |
Why?
| Metencephalon | 1 | 2022 | 1 | 0.200 |
Why?
| Cell Lineage | 2 | 2022 | 331 | 0.200 |
Why?
| Disease-Free Survival | 3 | 2016 | 646 | 0.200 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.190 |
Why?
| von Willebrand Diseases | 1 | 2022 | 24 | 0.190 |
Why?
| Genome, Human | 3 | 2014 | 394 | 0.190 |
Why?
| DNA Copy Number Variations | 4 | 2021 | 168 | 0.190 |
Why?
| von Willebrand Factor | 1 | 2022 | 71 | 0.190 |
Why?
| Spheroids, Cellular | 2 | 2012 | 77 | 0.190 |
Why?
| Radiation | 1 | 2021 | 23 | 0.180 |
Why?
| Pyridines | 3 | 2019 | 478 | 0.180 |
Why?
| Neural Stem Cells | 2 | 2012 | 142 | 0.180 |
Why?
| Tumor Microenvironment | 2 | 2022 | 627 | 0.180 |
Why?
| Mice, Transgenic | 3 | 2021 | 2128 | 0.170 |
Why?
| RNA, Long Noncoding | 2 | 2021 | 179 | 0.170 |
Why?
| Fatal Outcome | 1 | 2021 | 300 | 0.170 |
Why?
| Receptor, EphB4 | 1 | 2020 | 36 | 0.170 |
Why?
| Antigens, Surface | 2 | 1997 | 152 | 0.170 |
Why?
| Ephrin-B2 | 1 | 2020 | 50 | 0.170 |
Why?
| Colony-Forming Units Assay | 2 | 2012 | 90 | 0.170 |
Why?
| Craniospinal Irradiation | 1 | 2019 | 5 | 0.170 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 70 | 0.160 |
Why?
| Oncogene Proteins, Fusion | 2 | 2019 | 201 | 0.160 |
Why?
| RNA, Small Nuclear | 1 | 2019 | 35 | 0.160 |
Why?
| Receptors, Nerve Growth Factor | 1 | 2019 | 17 | 0.160 |
Why?
| Kaplan-Meier Estimate | 3 | 2017 | 851 | 0.160 |
Why?
| Karyopherins | 1 | 2019 | 19 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 3 | 2017 | 2011 | 0.160 |
Why?
| Benzamides | 3 | 2019 | 203 | 0.160 |
Why?
| Proteins | 3 | 2021 | 944 | 0.160 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2021 | 824 | 0.150 |
Why?
| Infant | 12 | 2021 | 8995 | 0.150 |
Why?
| Adolescent | 12 | 2021 | 20412 | 0.150 |
Why?
| Phenotype | 3 | 2024 | 3075 | 0.150 |
Why?
| Cell Self Renewal | 1 | 2019 | 53 | 0.150 |
Why?
| Male | 20 | 2021 | 63670 | 0.150 |
Why?
| Neoplasms | 2 | 2025 | 2455 | 0.150 |
Why?
| Base Sequence | 4 | 2012 | 2147 | 0.150 |
Why?
| Chemoradiotherapy | 1 | 2019 | 208 | 0.150 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 217 | 0.140 |
Why?
| Everolimus | 1 | 2017 | 88 | 0.140 |
Why?
| Cohort Studies | 6 | 2021 | 5426 | 0.140 |
Why?
| Sulfonamides | 2 | 2022 | 497 | 0.140 |
Why?
| Genes, p16 | 1 | 2017 | 19 | 0.140 |
Why?
| Recombinational DNA Repair | 1 | 2017 | 13 | 0.140 |
Why?
| DNA Damage | 2 | 2017 | 384 | 0.140 |
Why?
| E2F Transcription Factors | 1 | 2017 | 59 | 0.140 |
Why?
| DNA Methylation | 4 | 2021 | 611 | 0.140 |
Why?
| Morpholines | 1 | 2017 | 122 | 0.140 |
Why?
| Phthalazines | 1 | 2017 | 41 | 0.130 |
Why?
| Cell Division | 2 | 2010 | 796 | 0.130 |
Why?
| Chloroquine | 1 | 2017 | 51 | 0.130 |
Why?
| Stem Cells | 1 | 2021 | 575 | 0.130 |
Why?
| Benzodiazepinones | 1 | 2016 | 16 | 0.130 |
Why?
| Chromosome Aberrations | 1 | 2017 | 147 | 0.130 |
Why?
| Up-Regulation | 2 | 2016 | 840 | 0.130 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.130 |
Why?
| Microarray Analysis | 2 | 2017 | 116 | 0.130 |
Why?
| Immunophenotyping | 1 | 2017 | 311 | 0.130 |
Why?
| Electric Stimulation Therapy | 1 | 2017 | 77 | 0.130 |
Why?
| Urea | 1 | 2016 | 76 | 0.130 |
Why?
| Neoplasm Invasiveness | 2 | 2020 | 481 | 0.130 |
Why?
| Thiophenes | 1 | 2016 | 117 | 0.120 |
Why?
| Survival Analysis | 2 | 2010 | 1269 | 0.120 |
Why?
| Lysine | 2 | 2020 | 286 | 0.120 |
Why?
| Mitosis | 1 | 2016 | 180 | 0.120 |
Why?
| In Situ Hybridization, Fluorescence | 3 | 2025 | 313 | 0.120 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 432 | 0.120 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 187 | 0.120 |
Why?
| Tumor Suppressor Proteins | 1 | 2017 | 314 | 0.120 |
Why?
| Cancer Survivors | 1 | 2019 | 257 | 0.120 |
Why?
| Genomics | 3 | 2017 | 718 | 0.120 |
Why?
| HeLa Cells | 1 | 2016 | 612 | 0.120 |
Why?
| Promoter Regions, Genetic | 3 | 2017 | 1207 | 0.110 |
Why?
| Lymphocyte Activation | 2 | 2002 | 1109 | 0.110 |
Why?
| Retrospective Studies | 6 | 2025 | 14522 | 0.110 |
Why?
| Indoles | 1 | 2017 | 383 | 0.110 |
Why?
| Brain | 2 | 2020 | 2673 | 0.110 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 194 | 0.110 |
Why?
| Precision Medicine | 1 | 2017 | 387 | 0.100 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 778 | 0.100 |
Why?
| Flow Cytometry | 2 | 2019 | 1159 | 0.100 |
Why?
| Cell Movement | 2 | 2020 | 948 | 0.100 |
Why?
| Phosphorylation | 4 | 2020 | 1713 | 0.100 |
Why?
| Cathepsin B | 1 | 2012 | 13 | 0.100 |
Why?
| Wnt Proteins | 1 | 2014 | 127 | 0.100 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.100 |
Why?
| Argonaute Proteins | 1 | 2012 | 27 | 0.100 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 132 | 0.100 |
Why?
| Genomic Structural Variation | 1 | 2012 | 12 | 0.100 |
Why?
| Acetylcysteine | 1 | 2013 | 146 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 212 | 0.100 |
Why?
| Luciferases | 1 | 2012 | 147 | 0.100 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 138 | 0.100 |
Why?
| Gene Expression Regulation | 1 | 2021 | 2542 | 0.090 |
Why?
| Colorado | 1 | 2022 | 4404 | 0.090 |
Why?
| Quality of Life | 2 | 2023 | 2688 | 0.090 |
Why?
| Carrier Proteins | 2 | 2012 | 745 | 0.090 |
Why?
| Tubulin | 1 | 2012 | 138 | 0.090 |
Why?
| Carcinogenesis | 2 | 2025 | 213 | 0.090 |
Why?
| Telomerase | 1 | 2013 | 234 | 0.090 |
Why?
| Interleukin-6 | 1 | 2015 | 723 | 0.090 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2012 | 124 | 0.090 |
Why?
| Acetylation | 1 | 2011 | 244 | 0.090 |
Why?
| RNA Interference | 1 | 2012 | 450 | 0.090 |
Why?
| Acetaminophen | 1 | 2013 | 247 | 0.090 |
Why?
| Radiosurgery | 1 | 2014 | 321 | 0.090 |
Why?
| Adenosine | 1 | 2012 | 227 | 0.090 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2017 | 596 | 0.090 |
Why?
| Aging | 1 | 2020 | 1778 | 0.090 |
Why?
| Tyrosine | 2 | 2023 | 223 | 0.080 |
Why?
| Ki-67 Antigen | 2 | 2022 | 108 | 0.080 |
Why?
| Hydroxamic Acids | 2 | 2007 | 88 | 0.080 |
Why?
| Neoplasm Grading | 2 | 2021 | 282 | 0.080 |
Why?
| Superoxides | 1 | 2010 | 201 | 0.080 |
Why?
| Disease Models, Animal | 1 | 2019 | 4078 | 0.080 |
Why?
| Gene Silencing | 2 | 2007 | 190 | 0.080 |
Why?
| T-Lymphocytes | 1 | 1997 | 1936 | 0.080 |
Why?
| Kidney Neoplasms | 1 | 2013 | 348 | 0.080 |
Why?
| Histone Demethylases | 2 | 2022 | 31 | 0.070 |
Why?
| Cluster Analysis | 3 | 2017 | 482 | 0.070 |
Why?
| Down-Regulation | 1 | 2010 | 636 | 0.070 |
Why?
| Syndrome | 2 | 2005 | 340 | 0.070 |
Why?
| Nerve Tissue Proteins | 2 | 2012 | 569 | 0.070 |
Why?
| Scrotum | 1 | 2006 | 26 | 0.070 |
Why?
| Young Adult | 5 | 2021 | 12455 | 0.060 |
Why?
| Exocrine Pancreatic Insufficiency | 1 | 2005 | 20 | 0.060 |
Why?
| Premedication | 1 | 2005 | 42 | 0.060 |
Why?
| Transplantation Chimera | 1 | 2005 | 54 | 0.060 |
Why?
| Computer Simulation | 2 | 2021 | 939 | 0.060 |
Why?
| Anemia, Aplastic | 1 | 2005 | 36 | 0.060 |
Why?
| RNA | 1 | 2012 | 882 | 0.060 |
Why?
| Drug Synergism | 2 | 2017 | 370 | 0.060 |
Why?
| Neuroblastoma | 1 | 2006 | 151 | 0.060 |
Why?
| Molecular Sequence Data | 2 | 2008 | 2835 | 0.060 |
Why?
| Testicular Neoplasms | 1 | 2006 | 102 | 0.060 |
Why?
| Tissue Fixation | 1 | 2025 | 33 | 0.060 |
Why?
| Paraffin Embedding | 1 | 2025 | 29 | 0.060 |
Why?
| Neutropenia | 1 | 2005 | 137 | 0.060 |
Why?
| Formaldehyde | 1 | 2025 | 60 | 0.060 |
Why?
| Case-Control Studies | 1 | 2012 | 3378 | 0.060 |
Why?
| Transplantation Conditioning | 1 | 2005 | 166 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2274 | 0.060 |
Why?
| Treatment Outcome | 4 | 2024 | 10219 | 0.050 |
Why?
| Prodrugs | 1 | 2024 | 48 | 0.050 |
Why?
| Chromosomes | 1 | 2024 | 101 | 0.050 |
Why?
| Organophosphates | 1 | 2024 | 120 | 0.050 |
Why?
| Graft vs Host Disease | 1 | 2005 | 240 | 0.050 |
Why?
| Fluorouracil | 1 | 2024 | 197 | 0.050 |
Why?
| Core Binding Factor alpha Subunits | 1 | 2022 | 2 | 0.050 |
Why?
| Graft Survival | 1 | 2005 | 513 | 0.050 |
Why?
| Otx Transcription Factors | 1 | 2022 | 13 | 0.050 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2023 | 167 | 0.050 |
Why?
| Weibel-Palade Bodies | 1 | 2022 | 6 | 0.050 |
Why?
| fas Receptor | 1 | 2002 | 94 | 0.050 |
Why?
| Lymphoproliferative Disorders | 1 | 2002 | 54 | 0.050 |
Why?
| T-Box Domain Proteins | 1 | 2022 | 96 | 0.050 |
Why?
| Gene Ontology | 1 | 2021 | 49 | 0.050 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 102 | 0.050 |
Why?
| Antigens, CD | 3 | 2002 | 487 | 0.050 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 234 | 0.040 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 58 | 0.040 |
Why?
| Phagocytosis | 1 | 2023 | 362 | 0.040 |
Why?
| RNA Polymerase II | 1 | 2024 | 318 | 0.040 |
Why?
| Muscle Proteins | 1 | 2022 | 220 | 0.040 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 441 | 0.040 |
Why?
| Ifosfamide | 1 | 2020 | 34 | 0.040 |
Why?
| Follow-Up Studies | 2 | 2019 | 4894 | 0.040 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 217 | 0.040 |
Why?
| Transcription Factor HES-1 | 1 | 2019 | 5 | 0.040 |
Why?
| Smoothened Receptor | 1 | 2019 | 6 | 0.040 |
Why?
| Risk Factors | 3 | 2021 | 9786 | 0.040 |
Why?
| MyoD Protein | 1 | 2019 | 32 | 0.040 |
Why?
| Gain of Function Mutation | 1 | 2019 | 34 | 0.040 |
Why?
| Cyclophosphamide | 1 | 2020 | 234 | 0.040 |
Why?
| Astrocytoma | 1 | 2020 | 115 | 0.040 |
Why?
| RNA Splice Sites | 1 | 2019 | 44 | 0.040 |
Why?
| Apoptosis Regulatory Proteins | 2 | 1997 | 182 | 0.040 |
Why?
| Adult | 5 | 2021 | 35599 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 350 | 0.040 |
Why?
| Aminopyridines | 1 | 2019 | 98 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 281 | 0.040 |
Why?
| Autoimmune Diseases | 1 | 2002 | 427 | 0.040 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 1997 | 232 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 587 | 0.040 |
Why?
| RNA Splicing | 1 | 2019 | 260 | 0.040 |
Why?
| Consensus | 1 | 2021 | 618 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2002 | 708 | 0.040 |
Why?
| Transcription, Genetic | 1 | 2024 | 1418 | 0.040 |
Why?
| Drug Approval | 1 | 2018 | 87 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 25 | 0.040 |
Why?
| Alternative Splicing | 1 | 2019 | 217 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 19 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 32 | 0.030 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.030 |
Why?
| Homeodomain Proteins | 1 | 2021 | 494 | 0.030 |
Why?
| Transfection | 1 | 2019 | 915 | 0.030 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1997 | 149 | 0.030 |
Why?
| DNA, Complementary | 1 | 1997 | 270 | 0.030 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 119 | 0.030 |
Why?
| Jurkat Cells | 1 | 1997 | 134 | 0.030 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 91 | 0.030 |
Why?
| Global Health | 1 | 2019 | 328 | 0.030 |
Why?
| Radiotherapy | 1 | 2017 | 185 | 0.030 |
Why?
| Microscopy, Confocal | 1 | 2017 | 307 | 0.030 |
Why?
| Genetic Variation | 1 | 2021 | 939 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 367 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 338 | 0.030 |
Why?
| Macrophages | 1 | 2023 | 1488 | 0.030 |
Why?
| Canada | 1 | 2016 | 350 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 86 | 0.030 |
Why?
| Health Status | 1 | 2019 | 756 | 0.030 |
Why?
| Hematopoietic Stem Cells | 1 | 1997 | 382 | 0.030 |
Why?
| Zinc Finger Protein Gli2 | 1 | 2014 | 4 | 0.030 |
Why?
| Cytogenetics | 1 | 2014 | 12 | 0.030 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2014 | 19 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2014 | 55 | 0.030 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2014 | 56 | 0.030 |
Why?
| Myeloid Cells | 1 | 2015 | 142 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 528 | 0.030 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2014 | 67 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 67 | 0.030 |
Why?
| Gene Expression | 2 | 2010 | 1465 | 0.030 |
Why?
| Middle Aged | 3 | 2021 | 31136 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 171 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2017 | 1685 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2016 | 3394 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2013 | 382 | 0.020 |
Why?
| Gene Duplication | 1 | 2012 | 67 | 0.020 |
Why?
| Monocytes | 1 | 2015 | 553 | 0.020 |
Why?
| Translocation, Genetic | 1 | 2012 | 96 | 0.020 |
Why?
| Methylation | 1 | 2012 | 230 | 0.020 |
Why?
| B-Lymphocytes | 1 | 1997 | 816 | 0.020 |
Why?
| Inflammation Mediators | 1 | 2015 | 505 | 0.020 |
Why?
| Inflammation | 1 | 2023 | 2750 | 0.020 |
Why?
| Glutathione | 1 | 2013 | 348 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2014 | 1198 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 5455 | 0.020 |
Why?
| Genome | 1 | 2012 | 278 | 0.020 |
Why?
| Age Factors | 1 | 2017 | 3152 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2012 | 460 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1947 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1833 | 0.020 |
Why?
| Disease Progression | 1 | 2016 | 2627 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2019 | 5415 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 2021 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2014 | 3080 | 0.020 |
Why?
| Azacitidine | 1 | 2006 | 139 | 0.010 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2012 | 2060 | 0.010 |
Why?
| Risk Assessment | 1 | 2014 | 3262 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2512 | 0.010 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 88 | 0.010 |
Why?
| Receptors, Interleukin-2 | 1 | 2002 | 64 | 0.010 |
Why?
| Lectins, C-Type | 1 | 2002 | 71 | 0.010 |
Why?
| Cytoplasm | 1 | 2002 | 269 | 0.010 |
Why?
| Interleukin-4 | 1 | 2002 | 212 | 0.010 |
Why?
| Interleukin-2 | 1 | 2002 | 437 | 0.010 |
Why?
| Infant, Newborn | 1 | 2011 | 5756 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 2002 | 412 | 0.010 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2002 | 373 | 0.010 |
Why?
| Interferon-gamma | 1 | 2002 | 772 | 0.010 |
Why?
| Restriction Mapping | 1 | 1997 | 75 | 0.010 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 1997 | 28 | 0.010 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 1997 | 151 | 0.010 |
Why?
| Interleukin-7 | 1 | 1997 | 59 | 0.010 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1997 | 87 | 0.010 |
Why?
| Genes | 1 | 1997 | 227 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 1997 | 372 | 0.010 |
Why?
| Bone Marrow | 1 | 1997 | 273 | 0.010 |
Why?
| Calcium | 1 | 2002 | 1212 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1997 | 1250 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1997 | 2057 | 0.010 |
Why?
| Cells, Cultured | 1 | 1997 | 4084 | 0.010 |
Why?
|
|
Vibhakar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|